TY - JOUR
T1 - Efficient granulocyte collection method using high concentrations of medium molecular weight hydroxyethyl starch
AU - Kondo, Takumi
AU - Fujii, Keiko
AU - Fujii, Nobuharu
AU - Sumii, Yuichi
AU - Urata, Tomohiro
AU - Kimura, Maiko
AU - Matsuda, Masayuki
AU - Ikegawa, Shuntaro
AU - Washio, Kana
AU - Fujiwara, Hideaki
AU - Asada, Noboru
AU - Ennishi, Daisuke
AU - Nishimori, Hisakazu
AU - Matsuoka, Ken ichi
AU - Otsuka, Fumio
AU - Maeda, Yoshinobu
N1 - Publisher Copyright:
© 2023 AABB.
PY - 2023/7
Y1 - 2023/7
N2 - Background: Granulocyte transfusion therapy is a rational therapeutic option for patients with prolonged, severe neutropenia. Although high molecular weight hydroxyethyl starch (hHES) facilitates the separation of red blood cells during granulocyte collection, renal dysfunction has been noted as a potential side effect. HES130/0.4 (Voluven®) is a medium molecular weight HES (mHES) with superior safety profiles compared to hHES. Although HES130/0.4 is reportedly effective in the collection of granulocytes, we lack studies comparing the efficiency of granulocyte collection using HES130/0.4 and hHES. Study Design and Methods: We retrospectively collected the data from 60 consecutive apheresis procedures performed on 40 healthy donors at the Okayama University Hospital between July 2013 and December 2021. All procedures were performed using the Spectra Optia system. Based on the HES130/0.4 concentration in the separation chamber, granulocyte collection methods using HES130/0.4 were classified into m0.46, m0.44, m0.37, and m0.8 groups. We used HES130/0.4 and hHES groups to compare the various sample collection methods. Results: The median granulocyte collection efficiency (CE) was approximately 24.0% and 28.1% in the m0.8 and hHES groups, respectively, which were significantly higher than those in the m0.46, m0.44, and m0.37 groups. One month following granulocyte collection with HES130/0.4, no significant changes were observed in serum creatinine levels compared to those before the donation. Conclusion: Therefore, we propose a granulocyte collection approach employing HES130/0.4, which is comparable to the use of hHES in terms of the granulocyte CE. A high concentration of HES130/0.4 in the separation chamber was considered crucial for granulocyte collection.
AB - Background: Granulocyte transfusion therapy is a rational therapeutic option for patients with prolonged, severe neutropenia. Although high molecular weight hydroxyethyl starch (hHES) facilitates the separation of red blood cells during granulocyte collection, renal dysfunction has been noted as a potential side effect. HES130/0.4 (Voluven®) is a medium molecular weight HES (mHES) with superior safety profiles compared to hHES. Although HES130/0.4 is reportedly effective in the collection of granulocytes, we lack studies comparing the efficiency of granulocyte collection using HES130/0.4 and hHES. Study Design and Methods: We retrospectively collected the data from 60 consecutive apheresis procedures performed on 40 healthy donors at the Okayama University Hospital between July 2013 and December 2021. All procedures were performed using the Spectra Optia system. Based on the HES130/0.4 concentration in the separation chamber, granulocyte collection methods using HES130/0.4 were classified into m0.46, m0.44, m0.37, and m0.8 groups. We used HES130/0.4 and hHES groups to compare the various sample collection methods. Results: The median granulocyte collection efficiency (CE) was approximately 24.0% and 28.1% in the m0.8 and hHES groups, respectively, which were significantly higher than those in the m0.46, m0.44, and m0.37 groups. One month following granulocyte collection with HES130/0.4, no significant changes were observed in serum creatinine levels compared to those before the donation. Conclusion: Therefore, we propose a granulocyte collection approach employing HES130/0.4, which is comparable to the use of hHES in terms of the granulocyte CE. A high concentration of HES130/0.4 in the separation chamber was considered crucial for granulocyte collection.
KW - blood center operations
KW - cellular therapy
KW - therapeutic apheresis
UR - http://www.scopus.com/inward/record.url?scp=85161656418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85161656418&partnerID=8YFLogxK
U2 - 10.1111/trf.17450
DO - 10.1111/trf.17450
M3 - Article
C2 - 37293978
AN - SCOPUS:85161656418
SN - 0041-1132
VL - 63
SP - 1344
EP - 1353
JO - Transfusion
JF - Transfusion
IS - 7
ER -